Patient-derived organoids (PDO) are a new biomedical research model that can reconstruct
phenotypic and genetic characteristics of the original tissue and are useful for research on …

Droplet microfluidics is a powerful tool for a variety of biological applications including single-
cell genetics, antibody discovery and directed evolution. All these applications make use of …

Cancer patient classification using predictive biomarkers for anti-cancer drug responses is
essential for improving therapeutic outcomes. However, current machine-learning-based …

Pediatric low-grade gliomas (pLGG) show heterogeneous responses to MAPK inhibitors
(MAPKi) in clinical trials. Thus, more complex stratification biomarkers are needed to identify …

Fatty acid synthase, a key enzyme of de novo lipogenesis, is an attractive therapeutic target
in cancer. The novel fatty acid synthase inhibitor, TVB-3664, shows anti-cancer activity in …

For an increasing number of preclinical samples, both detailed molecular profiles and their
responses to various drugs are becoming available. Efforts to understand, and predict, drug …

Drug response prediction is important to establish personalized medicine for cancer therapy.
Model construction for predicting drug response (ie, cell viability half-maximal inhibitory …

The approval of the first kinase inhibitor, Gleevec, ushered in a paradigm shift for
oncological treatment—the use of genomic data for targeted, efficacious therapies. Since …

Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with a limited set of
known driver mutations but considerable cancer cell heterogeneity. Phosphoproteomics …

Background Considering the heterogeneity of tumors, it is a key issue in precision medicine
to predict the drug response of each individual. The accumulation of various types of drug …